Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ETHACRYNIC ACID vs EDECRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, potassium, and water. Also inhibits prostaglandin degradation.
Ethacrynic acid inhibits the Na-K-Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to diuresis.
Treatment of edema associated with congestive heart failure, cirrhosis, and renal disease,Treatment of ascites,Treatment of hypertension (off-label),Adjunctive therapy in acute pulmonary edema (off-label)
Treatment of edema associated with congestive heart failure, cirrhosis, and renal disease,Treatment of hypertension (off-label),Treatment of ascites (off-label),Management of hypercalcemia (off-label)
50 to 100 mg orally once daily; may increase by 25 to 50 mg increments at intervals of 2 to 3 days up to 400 mg/day. IV: 0.5 to 1 mg/kg slowly (over several minutes); usual initial dose 50 mg.
Oral: 50-100 mg once or twice daily, maximum 400 mg/day. IV: 50 mg (0.5 mg/kg) once, may repeat once at 2-hour intervals if needed.
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is 2-4 hours; prolonged in renal impairment (up to 30 hours) and in heart failure.
Primarily metabolized by conjugation with glutathione; also undergoes hepatic metabolism via CYP450 enzymes (minor).
Metabolized primarily in the liver, with approximately 30% excreted unchanged in urine and the remainder as metabolites, including the cysteine conjugate.
Primarily renal (approximately 60-70% as unchanged drug and metabolites) with some biliary/fecal excretion (approximately 30-40%).
Approximately 60-70% excreted unchanged in urine via glomerular filtration and tubular secretion; remaining 30-40% eliminated via biliary/fecal route.
Approximately 90-98% bound to plasma proteins, primarily albumin.
Approximately 95-98% bound, primarily to albumin.
Volume of distribution is approximately 0.1-0.2 L/kg, indicating limited extravascular distribution.
0.4-0.8 L/kg; reflects distribution primarily into extracellular fluid.
Oral bioavailability is approximately 100%.
Oral: approximately 50-70% due to first-pass metabolism; Intravenous: 100%.
e GFR 30-59 m L/min: no adjustment; e GFR <30 m L/min: avoid use due to risk of ototoxicity and decreased efficacy.
GFR 10-50 m L/min: 50% of normal dose. GFR <10 m L/min: not recommended or use with extreme caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Oral: 1 mg/kg/dose once daily; may increase by 1 mg/kg/dose at intervals of 2-3 days up to 3 mg/kg/day. IV: 1 mg/kg/dose slow IV; maximum 50 mg/dose.
Oral: 1-3 mg/kg/day in 1-2 divided doses. IV: 1 mg/kg/dose, maximum 50 mg/dose.
Initiate at lower doses (25 mg orally once daily) due to increased risk of electrolyte disturbances and renal impairment; monitor closely.
Start at lowest dose (25-50 mg oral daily) due to increased risk of electrolyte disturbances and hypotension.
This drug is a potent diuretic which, if given in excessive amounts, can lead to profound diuresis with water and electrolyte depletion. Close medical supervision and dose adjustment are required.
WARNING: EDECRIN is a potent diuretic which, if given in excessive amounts, can lead to profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dose schedule must be adjusted to the individual patient's needs.
Risk of excessive diuresis leading to dehydration, electrolyte imbalance, and hypovolemia,May cause ototoxicity, especially with rapid IV administration or in patients with renal impairment,Can worsen azotemia or precipitate hepatic encephalopathy in cirrhotic patients,Monitor serum electrolytes, CO2, BUN, and creatinine regularly,Use with caution in patients with diabetes mellitus (may increase blood glucose),May cause hyperuricemia and gout
Ototoxicity: Risk of hearing loss, especially with rapid IV administration or in patients with renal impairment; avoid concurrent use with other ototoxic drugs.,Volume and electrolyte depletion: Profound diuresis leading to dehydration, hypokalemia, hyponatremia, hypochloremia, and metabolic alkalosis.,Hypersensitivity reactions: Rash, eosinophilia, and anaphylaxis.,Gastrointestinal disturbances: Nausea, vomiting, diarrhea, and gastrointestinal bleeding (rare).,Hyperuricemia may precipitate gout.,Use with caution in patients with hepatic cirrhosis due to risk of hepatic encephalopathy.
Anuria,Hypersensitivity to ethacrynic acid or any component of the formulation,Severe electrolyte depletion (hypokalemia, hyponatremia) until corrected,Concurrent use with other ototoxic drugs (e.g., aminoglycosides) may increase risk
Anuria,Hypersensitivity to ethacrynic acid or any component of the formulation,Severe electrolyte depletion (e.g., hypokalemia, hyponatremia) until corrected,Concurrent use with other ototoxic agents (relative contraindication)
Avoid licorice, which can worsen hypokalemia. Limit salt intake as directed. No specific food interactions; maintain a balanced diet.
Avoid excessive intake of high-sodium foods as they can counteract the diuretic effect. Grapefruit juice may increase the risk of ototoxicity; consumption should be limited. Alcohol can exacerbate hypotension and dehydration. Ensure adequate potassium intake through diet (e.g., bananas, oranges) unless directed otherwise by a healthcare provider.
First trimester: Limited human data; animal studies show no teratogenicity but fetal toxicity at high doses. Second trimester: Theoretical risk of electrolyte imbalances affecting fetal development. Third trimester: Risk of premature ductus arteriosus closure due to prostaglandin inhibition (theoretical), neonatal ototoxicity, and thrombocytopenia.
EDECRIN (ethacrynic acid) is classified as FDA Pregnancy Category B. Limited human data; animal studies have not demonstrated teratogenic effects. However, diuretic use during pregnancy may reduce placental perfusion. Fetal risks include electrolyte disturbances, volume depletion, and possible growth restriction. Use only if clearly needed.
Safety not established. Drug excreted in breast milk; M/P ratio unknown. Avoid breastfeeding or use with caution due to potential for ototoxicity and electrolyte disturbances in the infant.
It is not known if ethacrynic acid is excreted in human milk. Due to potential adverse effects in the nursing infant, such as electrolyte imbalance, caution is advised. The manufacturer recommends discontinuing nursing or the drug, taking into account the importance of the drug to the mother. M/P ratio is unknown.
No standard dose adjustment; use lowest effective dose. Monitor for hypokalemia and volume depletion, which may be more pronounced in pregnancy. Consider adjusting dose based on maternal weight and renal function.
Pregnancy may alter pharmacokinetics; however, no specific dose adjustments have been established. Use lowest effective dose and shortest duration. Monitor for hypovolemia and electrolyte imbalances, which may be more pronounced in pregnancy.
Ethacrynic acid is a loop diuretic used for patients with sulfonamide allergy, as it is not a sulfonamide derivative. Monitor for ototoxicity, especially when given with aminoglycosides or in renal impairment. Rapid diuresis may cause hypokalemia, hypomagnesemia, and metabolic alkalosis. Use cautiously in hepatic cirrhosis to avoid electrolyte-induced coma.
EDECRIN (ethacrynic acid) is a potent loop diuretic that, unlike furosemide, is not a sulfonamide and can be used in patients with sulfonamide allergy. It can cause ototoxicity that is often irreversible, especially when given rapidly IV or with other ototoxic drugs like aminoglycosides. Monitor for hypokalemia, hypomagnesemia, and volume depletion. Use with caution in patients with hepatic cirrhosis due to risk of electrolyte-induced encephalopathy.
Take exactly as prescribed, usually once or twice daily.,Expect increased urination; take in the morning to avoid nighttime trips.,Weigh yourself daily and report rapid weight gain or loss.,Avoid alcohol and medications that may cause dizziness.,This drug may cause hearing loss or ringing in the ears; report immediately.,Do not take with aspirin or other NSAIDs without doctor approval.,Inform your doctor if you have gout, diabetes, or kidney disease.,Stay adequately hydrated but avoid excessive fluid intake.
Take this medication exactly as prescribed, usually once or twice daily.,Avoid alcohol and limit salt intake to reduce fluid retention.,Weigh yourself daily and report rapid weight gain or loss to your doctor.,Stand up slowly from sitting or lying down to prevent dizziness from low blood pressure.,Notify your doctor immediately if you experience hearing loss, ringing in the ears, or dizziness.,This drug may increase blood sugar; monitor if you have diabetes.,Avoid taking with other ototoxic medications like certain antibiotics without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ETHACRYNIC ACID vs EDECRIN, answered by our medical review team.
ETHACRYNIC ACID is a Loop Diuretic that works by Inhibits sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, potassium, and water. Also inhibits prostaglandin degradation.. EDECRIN is a Loop Diuretic that works by Ethacrynic acid inhibits the Na-K-Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ETHACRYNIC ACID and EDECRIN depend on the specific clinical indication. These are both Loop Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ETHACRYNIC ACID is: 50 to 100 mg orally once daily; may increase by 25 to 50 mg increments at intervals of 2 to 3 days up to 400 mg/day. IV: 0.5 to 1 mg/kg slowly (over several minutes); usual initial dose 50 mg.. The standard adult dose of EDECRIN is: Oral: 50-100 mg once or twice daily, maximum 400 mg/day. IV: 50 mg (0.5 mg/kg) once, may repeat once at 2-hour intervals if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ETHACRYNIC ACID and EDECRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ETHACRYNIC ACID is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity but fetal toxicity at high doses. Second trimester: Theoretical risk of electrolyte imbalances affecting . EDECRIN is classified as Category C. EDECRIN (ethacrynic acid) is classified as FDA Pregnancy Category B. Limited human data; animal studies have not demonstrated teratogenic effects. However, diuretic use during preg. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.